Taysha Gene Therapies (TSHA) Tops Q1 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $3.41 million versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral
• Kroger meets earnings expectations, revenue tops estimates